Source: FirstWord Pharma

OBT: Oxford BioTherapeutics, WuXi Bioligics ink deal to develop bispecific antibodies for cancer treatment

Oxford BioTherapeutics entered an expanded deal with WuXi Biologics potentially worth more than $450 million to develop five bispecific antibodies for the treatment of several cancer types using the latter's WuXiBody platform, the companies announced Tuesday. Under the agreed terms, WuXi Biologics will receive an undisclosed upfront payment as well as development, regulatory and commercial milestones, in addition to royalties based on global sales.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Christian Rohlff's photo - Founder & CEO of OBT

Founder & CEO

Christian Rohlff

CEO Approval Rating

86/100

OBT is a biotechnology company that focuses on the discovery and development of therapeutics for the treatment of cancer. Read more